UBS AM’s Design Therapeutics DSGN Stock Holding History

UBS AM’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.5K	Hold	1,143	–	–	﹤0.01%	3168
2026 Q1	$12.2K	Buy	1,143 +763	+201%	+$7.72K	﹤0.01%	3266
2025 Q4	$3.56K	Buy	+380	New	+$2.98K	﹤0.01%	3041

Other funds holding DSGN

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS AM's DSGN Position: Q2 2026 in Review

UBS AM held its Design Therapeutics (DSGN) position steady in Q2 2026 at 1,143 shares worth $16.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3168.

UBS AM first reported a position in DSGN in Q4 2025 and has held it in 3 quarters since. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

UBS AM held 1,143 shares of Design Therapeutics worth $16.5K as of Q2 2026.
UBS AM left its Design Therapeutics share count unchanged in Q2 2026.
Design Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3168 holding.
UBS AM first reported a position in Design Therapeutics in Q4 2025 and has held it in 3 quarters since.
137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.